not used title
not used title
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view.
Today, we are pleased to welcome a guest post from Phil Patent, a survivor of COVID-19 who continues to have long-term side effects from the virus. Phil is an advocate for continued medical innovation through Voters for Cures and is recommending everyone who is eligible get vaccinated against the virus.
I contracted COVID-19 one year ago, in July 2020. The disease almost took my life and I’m still suffering the aftermath today. Now as I watch caseloads rise in under-vaccinated regions of our country, I want desperately for people to hear my story so they can make good decisions about vaccination, for themselves, their families and their community.
I was 65 years old, just recently a senior citizen, when I had my brush with death. Only a few months before, I had undergone open heart surgery. Pre-existing heart disease, along with my age, put me at high risk of serious illness from COVID-19.
Despite my efforts to protect myself, I caught COVID-19 in July of 2020. I developed a deep cough and later struggled to breathe. Ultimately, I was admitted to the hospital, where I stayed for over two weeks. Thanks to attentive treatment and supportive therapies, I made it through. I was one of the lucky ones.
I credit the biopharmaceutical industry for saving my life. Even before many current, effective treatments were made available to patients, my doctors availed themselves of various medications to help my body cope during an intense viral onslaught.
As grateful as I am to have survived, my case isn’t a simple “happily ever after.” It’s been a full 12 months since I “recovered” and I’m still dealing with symptoms. Most frustrating, the damage to my lungs left me reliant on oxygen. I’m strapped to a canister at home and have to take a contraption everywhere I go. Obviously, this wasn’t the “return to normal” I’d envisioned.
That’s why it upsets me to hear people talk about COVID-19 as if it’s a passing illness, like a mild cold. First of all, a single unnecessary death from this virus is too many when we have the vaccine technology to help in most cases prevent it. What’s more, focusing solely on the mortality rate is to put blinders on to other devastating impacts of COVID-19.
Millions of people who contracted this disease are now, like me, long-haulers. Some pass out if they climb a set of stairs. Others suffer brain fog so bad they can barely work. Still others are dealing with fatigue, headaches, vision problems, psychiatric issues and more.
There’s no way I would take my chances with COVID-19 again. As soon my age group qualified, I received one of the authorized mRNA vaccines. After getting both doses, I felt immense relief for myself and was glad I’d helped protect others.
I wish more Americans would do the same. Stubbornness on vaccines is permitting the Delta variant to spread far and wide. Delta is more contagious than the COVID-19 I had and more likely to reinfect people – unless they get vaccinated. Only high rates of vaccination can suppress viral transmission, keep hospitals from being overwhelmed again, and help prevent further mutations, which could result in even more dangerous versions of COVID-19.
Take it from me, vaccination is the right choice. I got my shots nearly six months ago and was fine. On the other hand, catching COVID-19 almost cost me my life, stole my stamina, and left me permanently tied to an oxygen machine.
No one would voluntarily accept the outcome I now live with, but it’s the lottery you’re in if you remain unvaccinated. Please, don’t come to regret your decision – get your COVID-19 shots today.
Guest Contributor
The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view on issues facing our industry and the health care system.
Guest Contributor
New poll: 2 in 3 voters prefer a candidate committed to lowering health insurance premiums
September 18, 2026
Why smart vaccine policy matters
August 3, 2026
Voters continue to voice their concerns on government price controls
July 24, 2026
New study: HPV vaccination helps prevent cervical cancer deaths
July 21, 2026
Guest Blog: Price controls won’t lower costs when insurers control access
June 25, 2026
Patients speak out: MFN won't address my affordability concerns
June 4, 2026
New research reinforces the importance of hepatitis B vaccination at birth
May 21, 2026
World Immunization Week: Putting preventable diseases in the past
April 24, 2026
ICYMI: Measles resurgence could cost U.S. nearly $8 billion over five years
April 15, 2026
Why shifting childhood vaccines to “shared clinical decision-making” puts kids at risk
February 23, 2026
Changes to America’s childhood vaccine schedule fail to protect our nation's kids
January 13, 2026
New study: Measles setbacks harm health and America’s economy
October 28, 2025
Why the hepatitis B vaccine matters
October 21, 2025
Vaccines and autism: Decades of scientific evidence find no link
September 22, 2025
Why the vaccine injury program matters
August 18, 2025
Recognizing the importance of vaccination for American health and security
August 4, 2025
Answering common questions on mRNA technology
July 17, 2025
What to know about vaccine ingredients: Aluminum and thimerosal
June 24, 2025
World Immunization Week: Highlighting the importance of vaccines for public health
April 28, 2025
What you need to know: Measles and the MMR vaccine
March 10, 2025
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
February 25, 2025
Guest Perspective: Prioritize Innovative Care
February 11, 2025
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
February 3, 2025
Recognizing the value of disease prevention with Dr. Len Friedland from GSK
December 12, 2024
Leveraging the power of vaccines to prevent antimicrobial resistance
October 31, 2024
From the emergency department to the CDC Advisory Committee: Key takeaways from ACIP’s recent meeting
October 30, 2024
Guest Post: My health care vote
October 29, 2024
The Patient Perspective: Vaccines
October 23, 2024
Patient priorities in the 2024 election
September 10, 2024
How to protect your children’s health this school year
August 22, 2024
New Report: Vaccines continue to drive improved health outcomes
July 16, 2024
Showcasing the promise of biopharma at ASCO 2024
June 28, 2024
ICYMI: What patients care about this election year
June 24, 2024
World Vaccine Congress: Building on vaccine success
April 1, 2024
New poll: Americans agree that expanding the TRIPS waiver will harm U.S. global manufacturing and innovation leadership
January 29, 2024
WHO Pandemic Agreement offers opportunities and risks for American innovators
November 20, 2023
New Report: 1,600 cancer treatments and vaccines in clinical development
November 9, 2023
What you should know about protecting your health this fall
October 16, 2023
What you need to know: COVID-19 public health emergency is over, but ideological attacks on IP remain
September 12, 2023
Key considerations as Congress works towards PAHPA reauthorization
July 12, 2023
A conversation with Dr. Mike Ybarra on the current state of COVID-19
June 27, 2023
What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary
April 13, 2023
PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement
March 30, 2023
Celebrating the success of the COVID-19 vaccines, and looking to the future
March 27, 2023
PhRMA submits comments to OSTP on enhancing clinical trial diversity
March 21, 2023
What we’ve learned from three years of fighting COVID-19
March 20, 2023
U.S. must address IP and market access barriers abroad to protect American innovation
January 31, 2023
Word of the Month: What is TRIPS?
November 29, 2022
What you should know about RSV
November 15, 2022
TRIPS waiver expansion risks public health
November 14, 2022
Expanding the WTO intellectual property waiver will hurt American jobs
November 9, 2022
Word of the Month: Long COVID
October 19, 2022
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus
October 13, 2022
Partnerships are driving global COVID-19 treatment access
September 22, 2022
The dangers of expanding the TRIPS waiver
September 19, 2022
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines
August 16, 2022
ICYMI: Patients across the country are sharing concerns about government price setting
August 3, 2022
The Patient Perspective: Government price-setting harms patients
July 22, 2022
ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies
July 15, 2022
Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance
July 14, 2022
COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs
July 7, 2022
ICYMI: Antimicrobial resistance spotlighted as growing public health threat
July 6, 2022
Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful
May 23, 2022
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
May 13, 2022
ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond
May 9, 2022
A conversation with Barry Greene, CEO of Sage Therapeutics
May 4, 2022
ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19
April 28, 2022
Guest Post: If we truly want to cure complex diseases, politicians should reject price setting
March 14, 2022
New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year
February 24, 2022
What you need to know about newly authorized COVID-19 antiviral treatments
February 22, 2022
Guest post: Joining forces to combat the COVID-19 mental health crisis
February 17, 2022
Guest Blog: COVID-19 vaccines are the key to keeping kids healthy
February 16, 2022
Protecting U.S. innovation abroad to support economic and pandemic recovery
February 1, 2022
ICYMI: New report demonstrates growing global impact of antimicrobial resistance
January 24, 2022
Post-approval research save lives. Why is Congress trying disincentivize it?
December 17, 2021
Navigating the patient experience in the time of COVID-19
December 6, 2021
Global COVID-19 vaccination matters now and for the future
November 29, 2021
Guest post: Congress should not put future innovation at risk
November 29, 2021
Understanding breakthrough COVID-19 infections
November 11, 2021
PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19
October 29, 2021
The important role of antivirals in the fight against COVID-19
October 6, 2021
Understanding Long COVID-19
September 29, 2021
A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19
September 8, 2021
The impact of monoclonal antibodies and COVID-19 recovery
September 2, 2021
Recognizing National Immunization Awareness Month
August 31, 2021
Driving further innovation is critical to global vaccine equity
August 24, 2021
What they’re saying: Patient advocates want to protect Medicare from government interference
August 24, 2021
Supporting country readiness to boost global vaccine access
August 12, 2021
Ensuring global vaccine equity requires eliminating trade and regulatory barriers
August 5, 2021
Setting the record straight: Addressing common misconceptions about the COVID-19 vaccine
August 4, 2021
Increasing global access to vaccines by optimizing production
July 29, 2021
Guest post: Retired medics return to the field to take on vaccine delivery and disaster relief
July 23, 2021
Dose sharing as a part of the COVID-19 global vaccine equity strategy
July 20, 2021
Promoting global vaccine equity while protecting innovation
July 15, 2021
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
July 2, 2021
PhRMA awards $75,000 to fund initiatives to reduce health inequities
July 1, 2021
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
June 22, 2021
Americans 12 years of age and older are eligible for COVID-19 vaccines
June 17, 2021
PhRMA hosts first stakeholder workshop on clinical trial diversity
June 11, 2021
Coming together to fight COVID-19: A conversation with Barry Greene, CEO of Sage Therapeutics
June 9, 2021
A year later: Reflections on the meaning of equity
May 25, 2021
ICYMI: PhRMA president and CEO Stephen J. Ubl joins other industry leaders for a conversation on COVID-19 vaccines with Axios
May 21, 2021
Supporting India during the devastating coronavirus surge
May 20, 2021
New polling shows Americans are sounding the alarm on the TRIPS IP waiver
May 14, 2021
The Biden Administration allows politics to upend a pragmatic pandemic response
May 14, 2021
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
May 6, 2021
Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. on improving vaccine confidence in community
May 5, 2021
Reflecting on Mental Health Awareness Month
May 4, 2021
American leadership on innovation policy is essential to global health progress
May 4, 2021
Patient safety is at the heart of COVID-19 vaccine R&D
April 26, 2021
Data shows that Americans are relying on vaccines to get us through the pandemic
April 22, 2021
ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures
April 12, 2021
Diversifying clinical trials and fighting disease requires equity and trust
April 12, 2021
Building confidence in the COVID-19 vaccine through education
March 22, 2021
ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
March 8, 2021
Intellectual property is the key to vaccine development, manufacturing and technology sharing
March 5, 2021
Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
February 24, 2021
Fighting variants of COVID-19
February 22, 2021
ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response
February 22, 2021
Top five issues voters want addressed in the administration’s first 100 days
February 18, 2021
The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing
February 12, 2021
Lessons learned from COVID-19: The way we develop new medicines is changing
February 10, 2021
Growing trend: Increased vaccine confidence
January 28, 2021
Election insights: Common ground areas to address Americans’ health care concerns
January 26, 2021
Paper finds gaps in health data are a barrier to health equity
January 11, 2021
New research shows hotspots of inequity relate to increased COVID-19 hospitalizations
January 8, 2021
American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
December 21, 2020
Election insights: Voter priorities in the states
December 17, 2020
Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US
December 16, 2020
Insights from the election: Meeting voters where they are on health care
December 15, 2020
Coming together to fight COVID-19: A conversation with Kabir K. Nath, President & CEO of Otsuka North America Pharmaceutical Bu
December 9, 2020
Guest post: How COVID-19 underscores the importance of public confidence in vaccines
December 7, 2020
Guest Post: Bringing our best to the fight against COVID-19
December 3, 2020
An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb
November 18, 2020
Deep dive: The issues that drove the 2020 vote
November 13, 2020
Understanding the emergency use authorization process for COVID-19 vaccines
November 12, 2020
ICYMI: Addressing health inequities: Biopharmaceutical companies are rising to the occasion
November 2, 2020
U.S. trade policy must prioritize American biopharmaceutical innovation and patient access
November 2, 2020
Voters want to address the real drivers of health care costs for patients and the system
November 2, 2020
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
October 13, 2020
Flu Season 2020: Why it’s time to talk to your doctor today about getting a flu shot
October 8, 2020
Coming together to fight COVID-19: A conversation with Alexander Hardy, CEO of Genentech
October 1, 2020
Leading researchers to spotlight the critical role of biopharmaceutical R&D
October 1, 2020
Why the U.S. biopharmaceutical industry is leading the charge against COVID-19
September 30, 2020
Coming together to fight COVID-19: A conversation with Ramona Sequeira, President of Takeda Pharmaceuticals U.S.A
September 23, 2020
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
September 17, 2020
Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19
September 16, 2020
Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi
September 2, 2020
The 2020 We Work for Health Champion Awards showcase the best of our industry
August 27, 2020
Summer reading in the age of COVID-19
August 21, 2020
Supporting access to vaccines for Part D beneficiaries
August 12, 2020
The patient perspective navigating COVID-19
August 11, 2020
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
August 4, 2020
Executive order threatens R&D when we need it most to fight COVID-19
July 30, 2020
The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19
July 22, 2020
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
July 21, 2020
R&D Focus: 5 things to know about the biopharmaceutical research ecosystem
July 13, 2020
PhRMA’s Lori Reilly joined CSG to discuss the industry’s response to COVID-19 and what it means for states
July 13, 2020
New initiative to bridge the gap on antimicrobial innovation
July 9, 2020
Guest Post: Pride started with protest: Combatting the dual pandemics of COVID-19 and racism this Pride Month
June 30, 2020
How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective
June 29, 2020
In combating COVID-19, science is how we get back to normal
June 24, 2020
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
June 24, 2020
Guest post: A post-pandemic crisis: The mental toll on America
June 16, 2020
Guest Post: From lab to jab: Vaccine development to prevent COVID-19
June 11, 2020
PhRMA awards $100,000 to fund projects that address health inequalities
June 10, 2020
The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19
June 5, 2020
What scientific experts are saying about vaccine safety
June 4, 2020
Guest Post: Honoring Asian and Pacific Islander heritage in the age of COVID-19
May 29, 2020
IP Explained: Intellectual property system working to combat COVID-19
May 28, 2020
Guest Post: What will we learn from COVID-19?
May 27, 2020
Clinical Trials Awareness Week: Recognizing unsung heroes in medical research
May 18, 2020
What they are saying: Intellectual property protections are critical as we work to defeat COVID-19
May 4, 2020
Guest Post: Preserving clinical research sites during the coronavirus pandemic
April 29, 2020
Observing National Minority Health Month in the age of COVID-19
April 24, 2020
New report shows nearly 260 vaccines in development, including dozens for COVID-19
April 23, 2020
Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines
April 15, 2020
Guest post: Securing the health care supply chain during COVID-19
April 14, 2020
To the millions affected by COVID-19
April 9, 2020
New infographic: How we are fighting COVID-19
April 8, 2020
Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
April 6, 2020
The biopharmaceutical industry’s unique role in responding to COVID-19
April 2, 2020
ICYMI: America’s biopharmaceutical companies are working 'around the clock' to beat coronavirus
April 1, 2020
COVID-19 Response: Supporting the frontline
March 30, 2020
Guest post: Looking out for the invisibly vulnerable in the time of COVID-19
March 26, 2020
America’s biopharmaceutical companies are working around the clock to beat coronavirus
March 20, 2020
Guest post: Takeda’s efforts to address COVID-19
March 19, 2020
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
March 16, 2020
ICYMI: Continued biopharmaceutical action on COVID-19
March 6, 2020
Helping those affected by the coronavirus
February 20, 2020
Guest post: H.R.3 is the wrong approach to help patients like me
November 26, 2019
Guest post: Sharing discounts and rebates is the right thing to do
October 21, 2019
Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important
September 4, 2019
"If Washington isn’t careful, we might leave innovation behind"
June 24, 2019
Why vaccines work in the fight against measles and other infectious diseases
February 13, 2019
Medicare Monday: Helping beneficiaries access vaccines
December 18, 2017
New report and event examine the new era of vaccines
November 9, 2017